FNA Stock: Price, Forecast, Financials & AI Analysis

Loading...

High

--

Open

--

VWAP

--

Vol

--

Mkt Cap

551.63M

Low

--

Amount

--

EV/EBITDA(TTM)

--

Total Shares

--

EV

1.17B

EV/OCF(TTM)

--

P/S(TTM)

4.26

Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Company’s suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patient’s anatomical and surgical requirements.

Show More

Events Timeline

(ET)

2025-03-11

16:02:31

Paragon 28 announces expiration of HSR waiting period for pending acquisition

2025-01-28 (ET)

2025-01-28

17:02:36

Zimmer Biomet to acquire Paragon 28 for $13.00 per share in cash upfront

2025-01-14 (ET)

2025-01-14

11:00:49

Paragon 28 falls -9.5%

2025-01-13 (ET)

2025-01-13

07:25:45

Paragon 28 sees Q4 revenue $$71.5M-$71.8M , consensus $69.62M

2024-11-13 (ET)

2024-11-13

11:00:53

Paragon 28 rises 36.8%

News

an image of PRnewswire

2025-04-09PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AZEK, BRDG, FNA on Behalf of Shareholders

an image of Globenewswire

2025-04-02Globenewswire

$TOCKHOLDER ALERT: The M&A Class Action Firm Urges Shareholders of FNA, BECN, QTRX, PLYA to Take Action

an image of PRnewswire

2025-04-01PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MHLD, TURN, FNA, PTMN on Behalf of Shareholders

an image of NASDAQ.COM

2025-04-01NASDAQ.COM

After Hours Most Active for Apr 17, 2025 : INTC, CMCSA, KMI, NVDA, CCL, MRK, FNA, WBD, QQQ, T, VICI, TLT

an image of Globenewswire

2025-03-28Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, FNA, ML, JWN on Behalf of Shareholders

an image of PRnewswire

2025-03-26PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, TURN, AMPY on Behalf of Shareholders

5 Analyst Rating

Wall Street analysts forecast FNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FNA is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

5 Hold

0 Sell

Hold

Current: 0.000

Low

13.00

Averages

13.00

High

13.00

Current: 0.000

Low

13.00

Averages

13.00

High

13.00

Stephens & Co.

Mason Carrico

Buy

to

Hold

Downgrades

$14 → $13

Al Analysis

2025-01-30

Reason

Stephens & Co.

Mason Carrico

Price Target

$14 → $13

Al Analysis

2025-01-30

Downgrades

Buy

to

Hold

Reason

Stephens downgraded Paragon 28 (FNA) to Equal Weight from Overweight with a $13 price target after Zimmer Biomet (ZBH) agreed to acquire the company for $13 in cash per share plus up $1 per share in a contingent value right.

William Blair

Brandon Vazquez

Buy

to

Hold

Downgrades

n/a

2025-01-29

Reason

William Blair

Brandon Vazquez

Price Target

n/a

2025-01-29

Downgrades

Buy

to

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Paragon 28 Inc (FNA.N) is -27.89, compared to its 5-year average forward P/E of -39.31. For a more detailed relative valuation and DCF analysis to assess Paragon 28 Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-39.31

Current PE

-27.89

Overvalued PE

-17.17

Undervalued PE

-61.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

1.10

Current EV/EBITDA

238.72

Overvalued EV/EBITDA

714.20

Undervalued EV/EBITDA

-712.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

5.26

Current PS

3.75

Overvalued PS

7.45

Undervalued PS

3.07

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Paragon 28 Inc (FNA) stock price today?

The current price of FNA is 0 USD — it has increased 0 % in the last trading day.

What is Paragon 28 Inc (FNA)'s business?

Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Company’s suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patient’s anatomical and surgical requirements.

What is the price predicton of FNA Stock?

Wall Street analysts forecast FNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FNA is13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Paragon 28 Inc (FNA)'s revenue for the last quarter?

Paragon 28 Inc revenue for the last quarter amounts to 71.75M USD, increased 18.47 % YoY.

What is Paragon 28 Inc (FNA)'s earnings per share (EPS) for the last quarter?

Paragon 28 Inc. EPS for the last quarter amounts to -0.13 USD, decreased -45.83 % YoY.

How many employees does Paragon 28 Inc (FNA). have?

Paragon 28 Inc (FNA) has 574 emplpoyees as of January 17 2026.

What is Paragon 28 Inc (FNA) market cap?

Today FNA has the market capitalization of 551.63M USD.